This is a summary of the European public assessment report (EPAR) for Tybost. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Tybost.
For practical information about using Tybost, patients should read the package leaflet or contact their doctor or pharmacist.
Tybost : EPAR - Summary for the public (PDF/71.07 KB)
First published: 24/10/2013
Last updated: 24/10/2013
|Agency product number||
cobicistat on silicon dioxide
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Gilead Sciences Ireland UC
|Date of issue of marketing authorisation valid throughout the European Union||
08/04/2019 Tybost - EMEA/H/C/002572 - WS/1401
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antivirals for systemic use
Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human-immunodeficiency-virus-1 (HIV-1)-infected adults.